Received May 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | Y007623 | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y012077 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y010045 | — |
No additional AE; NSC Specialist transferred customer who reports a 13-month-old was inadvertently administered MMRII, PROQUAD and VARIVAX at the same time on 28APR2025. No symptoms reported. HCP agreed to correspondence. No additional AE/No PQC reported.; This spontaneous report was received from a Nurse and refers to a 13-month-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies, previous drug reactions and allergies were not reported. On 28-Apr-2025, the patient was inadvertently vaccinated with a dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) 0.5 mL, administered as prophylaxis (Lot No. Y007623 has been verified to be a valid lot number for [measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live], expiration date reported and upon internal validation established as 11-Apr-2026) (strength, dose number, route and anatomical location of administration and vaccination scheme frequency were not provided); also with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA [recombinant Human albumin]) (PROQUAD), 0.5 mL, administered as prophylaxis (Lot No. Y012077 has been verified to be a valid lot number for [measles, mumps, rubella and varicella (oka-merck) virus vaccine live], expiration date reported and upon internal validation established as 05-Jan-2026) (strength, dose number, route and anatomical location of administration and vaccination scheme frequency were not provided), and with a dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), 0.5 mL, administered as prophylaxis (Lot No. Y010045 has been verified to be a valid lot number for [varicella virus vaccine live (oka-merck)], expiration date reported and upon internal validation established as 29-May-2026) strength, dose number, route and anatomical location of administration and vaccination scheme frequency were not provided); all doses were reconstituted with sterile diluent (indication, Lot No., expiration date and route were not provided (accidental overdose). No additional adverse event was reported (No adverse event).
Sterile diluent